Global Coalition on Aging Workshop Calls on G7 Countries to Fund Pull Incentives to Spur Antibiotic Innovation

AMR is a major health threat in G7 countries, disproportionately impacting people with weakened immune systems, such as aging populations.

New York, NEW YORK (May 10, 2023) – The Global Coalition on Aging, in partnership with JPMA, today announced the release of its roundtable report on the AMR crisis facing G7 countries and the world, “The Value of Pull Incentives in Japan to Encourage Investment in Antibiotic Innovation to Solve the AMR Crisis.” If strong action is not taken to address AMR, we will lose the antibiotics we need to cure infections, which is likely to outpace cancer as a major cause of death, killing an estimated 10 million by 2050.

“Antimicrobial resistance is a serious challenge to all of us, but specifically to the promise of healthy aging,” said Michael Hodin, CEO of the Global Coalition on Aging. “G7 Leaders have an opportunity to solve this health crisis for everyone before it’s too late. We need unique policy levers and specific incentives to correct for the dangerous loss of antibiotic innovation.”

The Global Coalition on Aging (GCOA) convened a private workshop of experts and officials from Japan, Sweden, the United Kingdom, Italy and the United States to discuss how pull incentives within Japan and around the G7 could reinvigorate antibiotic innovation.

They found that:

  • The antimicrobials market can be revitalized by pull incentives worth between US$2.2 and US$4.5 billion per drug, paid over 10 years. This can be achieved if G7 countries contribute their fair share of funding to new incentives. As this year’s G7 Leader, Roundtable Participants called on Japan, especially, to meet its fair share of global funding (US$443 million per drug).
  • It is estimated that the world needs at least six new antimicrobial innovations per decade to make serious progress to solve the AMR crisis. This will only be possible through further funding for “pull” incentives, which delink revenue from sales volume, making it possible for manufacturers to support continued antimicrobial innovation without needing to actively sell new antimicrobials.
  • Antimicrobial incentives produce tremendous returns on investment for the societies that create them. Pull incentives will help countries around the world avoid serious economic and fiscal problems in the future due to AMR.

Antimicrobials, the foundation of modern healthcare systems, helped add an estimated average of 23 years to lifespans across the world during the latter part of the 20th century. An average one-fifth of G7 populations are currently over the age of 65, and as these societies age, they become more vulnerable to an infection without cure. At the same time, the effectiveness of antimicrobials is in crisis – the last time an entirely new class of antimicrobials was discovered was in the 1980s – weakening the ability of antimicrobials to treat infections.

The cost of inaction on antimicrobial innovation is far higher than the cost of action. In Japan, it is estimated that 19,600 deaths occur annually from just six priority pathogens with growing resistance to antimicrobials, at a cost to the health system of US$69,000 per death. Based on the cost of lost lives and costs to health systems of treatment, if Japan supported 18 new antimicrobials over a 30-year program with a fair share incentive of US$443 million per drug, the economic impact of that program would be US$8.92 billion and it would save 270,000 lives in Japan alone – a 28:1 return on investment (ROI). Across the entire G7, the ROI would be 23:1 over 30 years.

To read the report, please click here

About the Global Coalition on Aging

The Global Coalition on Aging aims to reshape how global leaders approach and prepare for the 21st century’s profound shift in population aging. GCOA uniquely brings together global corporations across industry sectors with common strategic interests in aging populations, a comprehensive and systemic understanding of aging, and an optimistic view of its impact. Through research, public policy analysis, advocacy, and strategic communications, GCOA is advancing innovative solutions and working to ensure global aging is a path for fiscally sustainable economic growth, social value creation and wealth enhancement.

For more information, visit: www.globalcoalitiononaging.com

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Global Coalition on Aging Workshop Calls on G7 Countries to Fund Pull Incentives to Spur Antibiotic Innovation

The Global Coalition on Aging, in partnership with JPMA, today announced the release of its workshop report on the AMR crisis facing G7 countries and the world, “The Value of Pull Incentives in Japan to Encourage Investment in Antibiotic Innovation to Solve the AMR Crisis.” If strong action is not taken to address AMR, we will lose the antibiotics we need to cure infections, which is likely to outpace cancer as a major cause of death, killing an estimated 10 million by 2050.

Our National Conversation on Aging

Now that President Biden officially declared his run for a second term, what are we to make of the countless warnings about his age? Clearly, voters have already considered age a major factor – Google Search results for ‘Biden age’ hit an all-time-high just before the 2020 election – and speculation has only heightened four years on. Unfortunately, these concerns are misguided and even dangerous because they conflate age with poor health and confuse ideas about work and retirement.

World Immunization Week: Best-Kept Secret for 21st-Century Healthy Aging

The tremendous success of childhood immunisation campaigns across the 20thcentury is one of the greatest triumphs of public health. Along with advances in sanitation and antibiotics, childhood immunisation has resulted in the miracle of modern longevity: the once extravagant prospect of growing old has become the norm. Now, in our 21st century, isn’t it our great challenge to build on this achievement by realising a healthy longevity?

South China Morning Post Letter to the Editor

Antimicrobial resistance is one of the defining global problems of our time. Drug-resistant bacterial infections killed an estimated 1.27 million people in 2019. By 2050, 10 million lives annually could be lost to antimicrobial resistance, and annual global gross domestic product could fall by between 1.1 per cent and 3.8 per cent. Fortunately, Chinese policymakers, physicians and patients have shown what is possible when they focus collective efforts on antimicrobial resistance.

Medicine Price Setting Might Appeal to Voters but Will Cost Patients

As policymakers search for potential cuts to the national budget, they risk jeopardizing the country’s most cost-effective use of healthcare dollars: biomedical innovation regarding vaccines , prescription drugs, and emerging therapies, including antibodies. As the nation rapidly ages, protecting this pipeline of medicine will not only improve health outcomes but will do so at a lower cost by reducing more expensive hospital and primary care.

Global Coalition on Aging Hosts Cross-Sector Roundtable to Tackle Heart Valve Disease in Aging Societies

The Global Coalition on Aging (GCOA) and the Global Heart Hub have released a global position paper “Heart Valve Disease: Harnessing Innovation to Save Lives, Mitigate Costs, and Advance the Healthy Aging Agenda.” The report builds upon on a December 2022 GCOA-GHH roundtable of cross-sector experts and examines how behavior and policy change can best address heart valve disease in our 21st century.

New York City Twins with Ireland to Develop Age Friendly Communities

The twinning commits both sides to share knowledge on age friendly programs and builds on the 2011 Dublin Declaration of Age-Friendly Cities and Communities. The agreement was signed by the Cathaoirleach (Mayor) Nick Killian of Meath County Council which hosts the Irish Age Friendly Programme and Lorraine Cortés-Vázquez, Commissioner for Aging.

Just Getting Started at 75

In the latest charge against the promise of healthy aging, Dr. Ezekiel Emanuel, oncologist and bioethicist, doubled down on his infamous 2014 essay stating that 75 is the ideal age to die. Now 65, he maintains that after age 75, he will no longer receive medical screenings and interventions like colonoscopies, cancer treatment, flu shots, and heart valve replacement.